Patents by Inventor Salvador Alonso

Salvador Alonso has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • USE OF CYP26-RESISTANT RAR ALPHA SELECTIVE AGONISTS IN THE TREATMENT OF CANCER
    Publication number: 20230310354
    Abstract: Disclosed herein are methods for treating a cancer comprising administering to a subject in need thereof an effective dose of a CYP26-resistant retinoic acid receptor (RAR) alpha (RAR?) selective agonist, whereby as a result of the treatment the tumor burden is reduced in the subject and cancer stem cells resident in the bone marrow are substantially reduced.
    Type: Application
    Filed: April 28, 2023
    Publication date: October 5, 2023
    Inventors: Gabriel Ghiaur, Richard J. Jones, Salvador Alonso, Roshantha A. Chandraratna
  • Use of CYP26-resistant RAR alpha selective agonists in the treatment of cancer
    Patent number: 11648222
    Abstract: Disclosed herein are methods for treating a cancer comprising administering to a subject in need thereof an effective dose of a CYP26-resistant retinoic acid receptor (RAR) alpha (RAR?) selective agonist, whereby as a result of the treatment the tumor burden is reduced in the subject and cancer stem cells resident in the bone marrow are substantially reduced.
    Type: Grant
    Filed: December 29, 2020
    Date of Patent: May 16, 2023
    Assignees: IO Therapeutics, Inc., The Johns Hopkins Univercity
    Inventors: Gabriel Ghiaur, Richard J. Jones, Salvador Alonso, Roshantha A. Chandraratna
  • USE OF CYP26-RESISTANT RAR ALPHA SELECTIVE AGONISTS IN THE TREATMENT OF CANCER
    Publication number: 20220184013
    Abstract: Disclosed herein are methods for treating a cancer comprising administering to a subject in need thereof an effective dose of a CYP26-resistant retinoic acid receptor (RAR) alpha (RAR?) selective agonist, whereby as a result of the treatment the tumor burden is reduced in the subject and cancer stem cells resident in the bone marrow are substantially reduced.
    Type: Application
    Filed: March 3, 2022
    Publication date: June 16, 2022
    Inventors: Gabriel Ghiaur, Richard J. Jones, Salvador Alonso, Roshantha A. Chandraratna
  • USE OF CYP26-RESISTANT RAR ALPHA SELECTIVE AGONISTS IN THE TREATMENT OF CANCER
    Publication number: 20210137866
    Abstract: Disclosed herein are methods for treating a cancer comprising administering to a subject in need thereof an effective dose of a CYP26-resistant retinoic acid receptor (RAR) alpha (RAR?) selective agonist, whereby as a result of the treatment the tumor burden is reduced in the subject and cancer stem cells resident in the bone marrow are substantially reduced.
    Type: Application
    Filed: December 29, 2020
    Publication date: May 13, 2021
    Inventors: Gabriel Ghiaur, Richard J. Jones, Salvador Alonso, Roshantha A. Chandraratna
  • USE OF CYP26-RESISTANT RAR ALPHA SELECTIVE AGONISTS IN THE TREATMENT OF CANCER
    Publication number: 20210137865
    Abstract: Disclosed herein are methods for treating a cancer comprising administering to a subject in need thereof an effective dose of a CYP26-resistant retinoic acid receptor (RAR) alpha (RAR?) selective agonist, whereby as a result of the treatment the tumor burden is reduced in the subject and cancer stem cells resident in the bone marrow are substantially reduced.
    Type: Application
    Filed: December 28, 2020
    Publication date: May 13, 2021
    Inventors: Gabriel Ghiaur, Richard J. Jones, Salvador Alonso, Roshantha A. Chandraratna
  • 1,4-dihydropyridine derivatives, a process for their preparation and their use for influencing the blood flow
    Patent number: 5691361
    Abstract: The invention relates to new 1,4-dihydropyridine derivatives of the general formula I ##STR1## in which R.sup.1, R.sup.2, R.sup.3 and n have the meaning stated in the patent claims.The compounds of the invention have a vasodilatory effect and are therefore suitable for the treatment of hypertension. Some of the compounds have a vasoconstrictory effect and can therefore be used for the treatment of hypotension.
    Type: Grant
    Filed: February 28, 1995
    Date of Patent: November 25, 1997
    Inventors: Carlos Sunkel, Miguel Fau De Casa-Juana, Luis Santos, Salvador Alonso, Antonio Garcia, Jaime Priego